Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Myeloma Expert Provides Insight on Practice-Changing Data

Danielle Bucco
Published: Friday, Mar 02, 2018

Jesus Berdeja, MD

Jesus Berdeja, MD
Novel therapeutic strategies presented over the last year shed light not only efficacious outcomes for patients with multiple myeloma, but also on improved supportive care methods, according to Jesus Berdeja, MD.

on Hematologic Malignancies.

FDA Approval of Denosumab

In January 2018, the FDA approved denosumab (Xgeva) for the prevention of skeletal-related events (SRE) in patients with multiple myeloma based on data from the phase III 482 study.1 In this trial, denosumab demonstrated noninferiority to zoledronic acid at delaying the time to the first SRE (HR, 0.98; 95% CI, 0.85-1.14; P = .01).
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x